Illumina (NASDAQ:ILMN) Shares Up 4.4% – Should You Buy?

Illumina, Inc. (NASDAQ:ILMN)’s stock price was up 4.4% during trading on Tuesday . The stock traded as high as $216.23 and last traded at $217.43. 428,010 shares traded hands during trading, a decline of 77% from the average session volume of 1,894,535 shares. The stock had previously closed at $208.21.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ILMN shares. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a research note on Wednesday, August 5th. Stifel Nicolaus increased their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research note on Monday, August 31st. Finally, Royal Bank Of Canada upped their target price on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $199.12.

Illumina Price Performance

The business has a fifty day simple moving average of $201.17 and a two-hundred day simple moving average of $163.08. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market cap of $33.97 billion, a PE ratio of 42.13, a P/E/G ratio of 2.93 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Keith Meister sold 119,501 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares of the company’s stock, valued at $168,244,440. This represents a 13.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,062,465 shares of company stock worth $436,589,802. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Elevation Wealth Partners LLC boosted its holdings in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares in the last quarter. Meeder Advisory Services Inc. increased its stake in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares in the last quarter. Gabelli Funds LLC raised its holdings in Illumina by 2.0% in the first quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company’s stock worth $616,000 after buying an additional 100 shares during the last quarter. MCF Advisors LLC raised its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares during the last quarter. Finally, WealthCollab LLC lifted its stake in shares of Illumina by 51.5% in the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock worth $37,000 after buying an additional 103 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.